Democritus University of Thrace (DUTH)
Η σχέση της κληρονομικής και επίκτητης θρομβοφιλίας με την πορεία της κύησης σε γυναίκες με αποβολές κυήματος: παλιοί και νέοι παράγοντες που επιδρούν στην κύηση και το όφελος της αντιπηκτικής αγωγής
Abstract
dc:descriptionBackground & Aims Fetal losses are a relatively common phenomenon with physical as well as psychological consequences for women. One of the most important factors influencing the outcome of a pregnancy and the occurrence of miscarriages is both the obstetric history as well as the age of the mother. The etiology of recurrent miscarriages is multifactorial, and in almost half of the cases no cause is found. There are factors that are generally accepted, such as antiphospholipid syndrome, while on the contrary, causes such as hereditary thrombophilia, remain controversial. It is a complex phenomenon due to genetic factors, acquired causes or more often a combination of both. The main hereditary factors of thrombophilia include the deficiency of natural coagulation inhibitors, factor V Leiden, prothrombin G20210A mutation, MTHFR mutation and hyperhomocysteinemia. The purpose of our study is to investigate hereditary and acquired thrombophilia in relation to the outcome of pregnancy, as well as the benefit of prophylactic anticoagulation in women during pregnancy. Materials & Methods This is a retrospective study of patients who were referred to the thrombophilia clinic of the Hematology Clinic of the University General Hospital of Alexandroupolis during the period 2003-2018. The study group included 175 women with an average age of 33 years. After obtaining consent, the complete medical history of the women was recorded. This involved the molecular control of mutations in factor V (FV Leiden, G1691A), prothrombin mutation (PTG, G20210A) and MTHFR mutations (C677T and A1286C) by PCR method, plasma determination of levels of natural coagulation inhibitors, resistance to activated protein C, lupus and homocysteine anticoagulants, and serum determination of levels of antiphospholipid antibodies. At the same time, a systematic review of the international literature was performed and then a meta-analysis of the data related to the administration of LMWH in women with recurrent miscarriages with or without thrombophilia. From 12 RCTs included in this meta-analysis we identified records from 2298 women. Results The birth rate of live newborns as the primary endpoint of the study amounts to 86.8% and the late obstetric complications to 9.8%. The prevalence of thrombophilia in our study was 33.5%. Specifically, FV Leiden mutation showed 14.3%, prothrombin mutation 4.5% and deficiency of natural anticoagulants 5.1%. Antiphospholipid syndrome was diagnosed in 4.5%. The incidence of the MTHFR mutation was 4.5%. Following the correlation of all the parameters with that of the birth of a live newborn it was concluded that only age is negatively related to the live birth rate LBR (OR = 0.904, 95% CI = 0.818 - 1.00, p = 0.049). Using the characteristic ROC curve, the age cutoff for abortion was set at 35.5 years (Area below the ROC curve: 0.698, p = 0.007). The results of the meta-analysis on the benefit of using LMWH by women with thrombophilia resulting in live birth rate are not statistically significant, but the heterogeneity of studies is statistically significant (OR = 2.09, 95% CI = 0.58–7.57, p = 0.26, I2 = 86%, p = 0.0001). The use of LMWH towards the birth of a live newborn proved to be of no benefit to women without thrombophilia and the data of these clinical studies are characterized by low heterogeneity (OR = 1.25, 95% CI = 0.88–1.78, p = 0, 21, I2 = 44%, p = 0.07). Conclusions Thrombophilic disorders are more common in women with miscarriages and obstetric events, but the severity or type of thrombophilia does not affect live birth rates or the incidence of obstetric complications. Maternal age is the only factor negatively related to the live birth rate. LMWH is not recommended for women who suffer miscarriages with or without hereditary thrombophilia. However, prophylaxis with LMWH in women with recurrent miscarriages, although not well documented, remains the only available and safe treatment for women experiencing obstetric events.
Degree
thesis:*- Grantor dc:publisher
- Democritus University of Thrace (DUTH)
- Year dc:date
- 2022
Author and committee
dc:creator, dc:contributor.*- Authors dc:creator
-
- Stamou, Maria
- Στάμου, Μαρία
Subjects
dc:subject × 16- Κληρονομική θρομβοφιλία
- Επαναλαμβανόμενες αποβολές κυήματος
- Ηπαρινή χαμηλού μοριακού βάρους
- Αντιφωσφολιπιδικό σύνδρομο
- Hereditary thrombophilia
- Miscarriage, Recurrent
- Low molecular weight heparin (LMWH)
- Antiphospholipid syndrom
- Κλινική Ιατρική
- Ιατρική και Επιστήμες Υγείας
- Αιματολογία
- Μικροβιολογία (ιατρική)
- Clinical Medicine
- Medical and Health Sciences
- Hematology
- Microbiology (medical)
Rights
- Language dc:language
- gre
Identifiers
dc:identifier.*- Identifier
- 10.12681/eadd/51308